US Stock MarketDetailed Quotes

BPMC Blueprint Medicines

Watchlist

96.570
+6.150+6.80%

Close Feb 28 16:00 ET

96.570
0.0000.00%

Post 20:01 ET

6.17BMarket Cap-90.25P/E (TTM)

Blueprint Medicines Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Blueprint Medicines Q4 2024 Earnings Date

Currency：USDFeb 13, 2025

	Estimate (YoY)	Actual (YoY)	Vs Estimate (% Chg)
Revenue	145.18M	146.37M	+1.18M
Beat Est.	+101.76%	+103.41%	+0.82%
EPS	-0.71	-0.79	-0.08
Miss Est.	+61.02%	+56.59%	-11.36%

Analyst Rating

Strong Buy

Mar 2, 2025

Blueprint Medicines Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 17 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual

Estimate

Date	Period	Revenue/Estimate	Earnings Call
--	2025/Q2	-- / 175.850M	--
--	2025/Q1	-- / 159.071M	--
Feb 13, 2025	2024/Q4	146.366M / 145.182M	--
Oct 30, 2024	2024/Q3	128.184M / 127.466M	--
Aug 1, 2024	2024/Q2	138.157M / 103.938M	--

DatePeriodRevenue/EstimateEarnings Call

--2025/Q2-- / 175.850M--

--2025/Q1-- / 159.071M--

Feb 13, 20252024/Q4146.366M / 145.182M--

Oct 30, 20242024/Q3128.184M / 127.466M--

Aug 1, 20242024/Q2138.157M / 103.938M--

Unlock Free Earnings Estimates

Open Account

Blueprint Medicines Earnings Reports

Blueprint Medicines | 10-K: FY2024 Annual Report

Feb 13 17:15 ET

Blueprint Medicines | 8-K: Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

Feb 13 07:39 ET

Blueprint Medicines | 10-Q: Q3 2024 Earnings Report

Oct 30, 2024 16:32 ET

Blueprint Medicines | 8-K: Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance

Oct 30, 2024 07:11 ET

Trending Stocks

Symbol Mini Chart % Chg

Halozyme Therapeutics

HALO

+2.51%